4//SEC Filing
Kaplan Matthew L. 4
Accession 0001104659-22-060910
CIK 0001875558other
Filed
May 15, 8:00 PM ET
Accepted
May 16, 8:32 AM ET
Size
7.4 KB
Accession
0001104659-22-060910
Insider Transaction Report
Form 4
Kaplan Matthew L.
Director
Transactions
- Purchase
Common Stock
2022-05-12$15.96/sh+1,177$18,785→ 33,937 total - Purchase
Common Stock
2022-05-12$17.47/sh+1,823$31,848→ 35,760 total
Footnotes (2)
- [F1]Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.75 to $16.00. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F2]Reflects the weighted average purchase price. The range of prices for the shares purchased was $17.33 to $17.50. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
Documents
Issuer
Nuvectis Pharma, Inc.
CIK 0001875558
Entity typeother
Related Parties
1- filerCIK 0001895952
Filing Metadata
- Form type
- 4
- Filed
- May 15, 8:00 PM ET
- Accepted
- May 16, 8:32 AM ET
- Size
- 7.4 KB